Skip Navigation


Rheumatology Advance Access originally published online on November 30, 2004
Rheumatology 2005 44(3):386-389; doi:10.1093/rheumatology/keh499
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
44/3/386    most recent
keh499v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Majithia, V.
Right arrow Articles by Harisdangkul, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Majithia, V.
Right arrow Articles by Harisdangkul, V.
Related Collections
Right arrow Osteoarthritis and Cartilage
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology Vol. 44 No. 3 © British Society for Rheumatology 2004; all rights reserved

Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy

V. Majithia and V. Harisdangkul

Division of Rheumatology, University of Mississippi Medical Center, Jackson, Mississippi, USA.

Correspondence to: vmajithia{at}medicine.umsmed.edu

Objectives. Mycophenolate mofetil (MMF) is a new immunosuppressive agent currently being used for the prevention of renal allograft rejection. MMF is a specific inhibitor of lymphocytes and is well tolerated leading to its use in other autoimmune diseases. We have used MMF for the treatment of seven patients with inflammatory myopathy and are hereby reporting our results.

Case series. All of our patients were females (age 17–65 yr). They were symptomatic upon presentation and met classification criteria for idiopathic inflammatory myopathy. Inflammatory markers such as erythrocyte sedimentation rate and C-reactive protein as well as creatine kinase were significantly elevated in all the patients, indicating active disease. Corticosteroids were concomitantly being administered (20–60 mg/day of prednisone). Initial therapy with conventional immunosuppressives was either ineffective or had significant adverse effects leading to their discontinuation. MMF was started in doses of 500 mg twice a day and titrated up to 1 g twice a day.

Results. Our patients have exhibited an impressive serological response to therapy with MMF and six patients had a marked improvement in their weakness. One patient had incomplete improvement in her weakness and has required additional therapies. MMF has been well tolerated during the treatment period (12–36 months).

Conclusion. A striking clinical and laboratory response of active myositis in six out of seven patients in this series illustrates that MMF can be effectively used in management of autoimmune inflammatory myopathy and may be a suitable alternative to the conventional immunosuppressive agents.

KEY WORDS: Mycophenolate mofetil, autoimmune inflammatory myopathy, immunosuppressives


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
C. N. Pisoni, M. J. Cuadrado, M. A. Khamashta, G. R. V. Hughes, and D. P. D'Cruz
Mycophenolate mofetil treatment in resistant myositis
Rheumatology, March 1, 2007; 46(3): 516 - 518.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
A C Cordeiro and D A Isenberg
Treatment of inflammatory myopathies.
Postgrad. Med. J., July 1, 2006; 82(969): 417 - 424.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. Rowin, A. A. Amato, N. Deisher, J. Cursio, and M. N. Meriggioli
Mycophenolate mofetil in dermatomyositis: Is it safe?
Neurology, April 25, 2006; 66(8): 1245 - 1247.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.